Loading...
•
Dec 31, 2024
MannKind Q4 2024 Earnings Report
MannKind reported strong revenue growth and improved net income in Q4 2024, driven by increased royalties, collaborations, and commercial sales.
Key Takeaways
MannKind Corporation delivered robust financial results in the fourth quarter of 2024, with total revenues increasing by 31% year-over-year to $76.776 million and net income reaching $7.422 million, a significant improvement from the previous year. The company also reported a non-GAAP net income of $22.952 million.
Total revenues for Q4 2024 increased by 31% to $76.776 million compared to Q4 2023.
Net income for Q4 2024 was $7.422 million, a substantial increase from $1.401 million in Q4 2023.
Non-GAAP net income for Q4 2024 was $22.952 million, up from $7.147 million in Q4 2023.
The company reported basic EPS of $0.03 for Q4 2024, compared to $0.01 in Q4 2023.
Revenue by Segment
Forward Guidance
MannKind anticipates continued growth and progress across its pipeline, including regulatory submissions for Afrezza in pediatrics, advancement of MNKD-201, and meeting enrollment targets for MNKD-101.
Positive Outlook
- Planned submission for Afrezza approval in the pediatric population in summer 2025.
- Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into next phase of development.
- Expect to meet the interim enrollment target for Clofazimine Inhalation Suspension Phase 3 (ICON-1) by YE 2025.
- Afrezza approved in India for adults, with shipments expected in 4Q 2025.
- Anticipate supplemental new drug application filing for Afrezza in 1H 2025 pending FDA feedback.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...